RESEARCH
Blood vessels are essential for proper functioning of tissues and organs in our body, and vascular dysfunction is associated with many cardiovascular and neurodegenerative diseases. Insight into the interactions between vascular cells and the local microenvironment are therefore key to understanding many different diseases. Human induced pluripotent stem cells (hiPSCs) derived from patients with genetic vascular disorders can form blood vessel cells and provide human models for disease that can be used to find new therapeutics and strategies for disease prevention.
DIFFERENTIATION OF HIPSCS
We utilize hiPSCs derived from healthy donors and patients with genetic vascular disorders. Over recent years, we have developed efficient protocols to differentiate different endothelial cell (EC) subtypes, pericytes, vascular smooth muscle cells, as well as myeloid cells, such as monocytes and macrophages. Specifically we investigate the generation of tissue-specific vascular cells with focus on the heart and brain vasculature.
VESSELS ON A CHIP
We trying to recreate both micro- and macrovascular- structures inside of microfluidic devices. For this we use modling approach to create tubes of around 100-150um in diameter and
self-organisation in microfluidic devices or chips, to create perfused micro-vessels on average 10-50um in diameter. Additionally, we are exploring photopatterning technologyto to recreate the same pattern repeatedly and thus eventually make micron-size self-organised structures of endothelial cell tubes.
DISEASE MODELS
Using these 3D vessels on a chip and hiPSC from patients we aim to develop realistic disease models for hereditary hemorrhagic telangiectasia (HHT) and cerebral amyloid angiopathy (CAA), and model tumour angiogenesis and inflammation with patient-specific hiPSCs.
RNA-SEQ
Using CRISPR/Cas9 based gene targeting, we have generated several fluorescent reporter hiPSC lines for core transcriptional factors (TF) that are being used to advance our understanding of lineage specification and differentiation of ECs with different mesodermal origins and distinguishable by their core transcriptional signature.
PEOPLE
LISA VAN DEN HIL
Research Technician
XU CAO
PhD Student
DR. AMY COCHRANE
PostDoc
DR. MARC VILA CUENCA
PostDoc
MEES DE GRAAF
PhD Student
DENNIS NAHON
PhD Student
DHANESH KASI
PhD Student
ULGU ARSLAN
PhD Student
MERVE BULUT
PhD Student
Former Lab Members
Giacomelli E, Meraviglia V, Campostrini G, Cochrane A, Cao X, Helden R W J van, Garcia A K, Mircea M, Kostidis S, Davis R P, Meer B J van, Jost C R, Koster A J, Mei H, Míguez D G, Mulder A A, Ledesma-Terrón M, Pompilio G, Sala L, Salvatori D C F, Slieker R C, Sommariva E, Vries A A F de, Giera M, Semrau S, Tertoolen L G J, Orlova V V, Bellin M and Mummery C L. 2020.
de Graaf MSN, Cochrane A, van den Hil FE, Buijsman W, van der Meer A, van den Berg A, Mummery CL, Orlova VV. APL Bioengineering. 2019.
doi: 10.1063/1.5090986
Cao X, Yakala GK, van den Hil FE, Cochrane A, Mummery CL, Orlova VV. Stem Cell reports. 2019.
doi: 10.1016/j.stemcr.2019.05.003
Halaidych OV, Mummery CL, Orlova VV. BBRC. 2019.
doi: 10.1016/j.bbrc.2019.03.143
Halaidych OV, Cochrane A, van den Hil FE, Mummery CL, Orlova VV. Stem Cell Reports. 2019.
doi: 10.1016/j.stemcr.2019.02.003
Halaidych OV, van den Hil FE, Mummery CL, Orlova VV. JoVE. 2018. doi: 10.3791/58678
Cochrane A, Albers HJ, Passier R, Mummery CL, van den Berg A, Orlova VV, van der Meer AD.
Adv Drug Deliv Rev. 2018 Jun 23. pii: S0169-409X(18)30146-7. doi: 10.1016/j.addr.2018.06.007.
Halaidych OV, Freund C, van den Hil F, Salvatori DCF, Riminucci M, Mummery CL, Orlova VV. Stem Cell Reports. 2018 May 8;10(5):1642-1656. doi: 10.1016/j.stemcr.2018.03.012.
Guadix JA, Orlova VV, Giacomelli E, Bellin M, Ribeiro MC, Mummery CL, Pérez-Pomares JM, Passier R.
Stem Cell Reports. 2017 Dec 12;9(6):1754-1764. doi: 10.1016/j.stemcr.2017.10.023.
Giacomelli E, Bellin M, Sala L, van Meer BJ, Tertoolen LG, Orlova VV, Mummery CL.
Development. 2017 Mar 15;144(6):1008-1017. doi: 10.1242/dev.143438
Birket MJ, Ribeiro MC, Verkerk AO, Ward D, Leitoguinho AR, den Hartogh SC, Orlova VV, Devalla HD, Schwach V, Bellin M, Passier R, Mummery CL.
Nat Biotechnol. 2015 Sep;33(9):970-9. doi: 10.1038/nbt.3271
Orlova V, Mummery C.
Cell Stem Cell. 2016 Mar 3;18(3):422. doi: 10.1016/j.stem.2016.02.013
Passier R, Orlova V, Mummery C.
Cell Stem Cell. 2016 Mar 3;18(3):309-21. doi: 10.1016/j.stem.2016.02.011. Review
Orlova VV, van den Hil FE, Petrus-Reurer S, Drabsch Y, Ten Dijke P, Mummery CL.
Nat Protoc. 2014;9(6):1514-31. doi: 10.1038/nprot.2014.102
Orlova VV, Drabsch Y, Freund C, Petrus-Reurer S, van den Hil FE, Muenthaisong S, Dijke PT, Mummery CL.
Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):177-86. doi: 10.1161/ATVBAHA.113.302598
van der Meer AD, Orlova VV, ten Dijke P, van den Berg A, Mummery CL.
Lab Chip. 2013 Sep 21;13(18):3562-8. doi: 10.1039/c3lc50435b